Alpha Tau Medical stock heads for TA-90, TA-125 inclusion

Published on 11/11/2026 at 02:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alpha Tau Medical stock is set to enter two Tel Aviv benchmarks after its dual listing. The move could broaden access for Israeli investors.

Index inclusion supports local market visibility

Alpha Tau is developing Alpha DaRT for several solid-tumor indications across international clinical programs.
The Tel Aviv listing adds a local trading venue and was expected to precede inclusion in two widely followed benchmarks.

Alpha Tau Medical stock, Alpha DaRT, Tel Aviv Stock Exchange, TA-90, TA-125, oncology, Illustration mit AI erstellt.

Alpha Tau Medical is heading toward inclusion in the Tel Aviv Stock Exchange's TA-90 and TA-125 indexes, a move the exchange said was expected for November 5, 2026. The Tel Aviv Stock Exchange reported the planned addition in a release dated October 26, when Alpha Tau management opened trading to mark the company's dual listing.

The index move follows Alpha Tau's addition to TASE after its Nasdaq listing. The exchange said the shares were expected to join the flagship benchmarks in the next semiannual index update, potentially widening the company's reach among Israeli market participants and index-tracking funds.

Clinical pipeline remains central

Alpha Tau is developing Alpha DaRT, an intratumoral alpha-radiation treatment for solid tumors. TASE said the company has clinical programs in Israel, North America, Europe and Asia, including work in skin cancer, glioblastoma and pancreatic cancer.

The exchange also cited a February 2026 marketing approval in Japan for head and neck cancer and a June collaboration with Tolmar to commercialize Alpha DaRT for prostate cancer in the United States. Those milestones give the index inclusion a broader capital-markets context, but the treatment remains tied to clinical and regulatory execution.

Alpha Tau's oncology position

Alpha Tau is a Jerusalem-based, clinical-stage oncology therapeutics company focused on Alpha DaRT for multiple solid-tumor indications. Its platform is designed for direct tumor delivery and is being developed through global clinical programs rather than through an established commercial product portfolio. TASE identifies Tolmar as a US pharmaceutical collaboration partner in urology and oncology; the available company information does not establish a separate competitive ranking against named peers.